The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
